Incidence of inhibitors in haemophilia A patients - a review of recent studies of recombinant and plasma-derived factor VIII concentrates

Haemophilia

Volumn 5, Issue 3, 1999, Pages 145-154

  Scharrer, I ^a   Bray, G L ^b   Neutzling, O ^c  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b BAXTER HEALTHCARE CORPORATION   (United States)

^c Hyland Immuno Division   (Germany)

Author keywords

Clinical studies; Haemophilia A; Incidence; Inhibitors; Prevalence; Recombinant factor VIII

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8;

CHROMOSOME INVERSION; CLINICAL TRIAL; GENE DELETION; GENE MUTATION; HEMOPHILIA A; HUMAN; INTRON; ISOCHROMOSOME; NONSENSE MUTATION; PLASMA; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ADULT; ANTIBODIES; CHILD; CHILD, PRESCHOOL; FACTOR VIII; HEMOPHILIA A; HUMANS; RECOMBINANT PROTEINS; RISK FACTORS;

EID: 0032787813     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.1999.00300.x     Document Type: Review

References (61)

1. Rasi V, Ikkala E. Haemophiliacs with factor VIII inhibitors in Finland: Prevalence, incidence and outcome. Br J Haematol 1990; 76: 369-71.
2. Nilsson IM, Berntorp E. Induction of immune tolerance in hemophiliacs with inhibitors, by combined treatment with IVIG, cyclophosphamide and factor VIII or IX - the Malmö Model. Immunotherapy with Intravenous Immunoglobulins. Academic Press Ltd, 1991, 333-44.
3. Knöbl P, Derfler K, Korninger L, et al. Elimination of acquired factor VIII antibodies by extracorporal antibody-based immunoadsorption (Ig-Therasorb). Thromb Haemost 1995; 74: 1035-8.
4. Strauss HS. Acquired circulating anticoagulants in hemophilia A. N Engl J Med 1969; 281: 866-73.
5. Biggs R. Jaundice and antibodies directed against factors VIII and IX in patients treated for haemophilia or Christmas disease in the United Kingdom. Br J Haematol 1974; 26: 313-29.
6. Brinkhous KM, Roberts HR, Weiss AE. Prevalence of inhibitors in hemophilia A and B. Thromb Diath Haemorrh 1972; (Suppl. 51): 315-21.
7. Gill FM. The natural history of factor VIII inhibitors in patients with hemophlilia A. Prog Clin Biol Res 1984; 150: 19-29.
8. Roberts HR. Antigenicity of highly purified factor VIII concentrates. Blood Coagulation Fibrinolysis 1991; 2 (Suppl. 1): 21-3.
9. Lusher JM, Salzman PM. Viral safety and inhibitor development associated with factor VIIIC ultra-purified from plasma in haemophiliacs previously unexposed to factor VIIIC concentrates. Semin Hematol 1990; 27 (Suppl. 2): 1-7.
10. Lusher JM. Viral safety and inhibitor development associated with monoclonal antibody-purified FVIIIC. Ann Hematol 1991; 63: 138-41.
11. Addiego JE, Gomperts E, Liu S, et al. Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIc immunoaffinity chromatography. Thromb Haemost 1992; 67: 19-27.
12. Kessler CM, Sachse K. Factor VIII: C inhibitor associated with monoclonal-antibody purified FVIII concentrate (letter). Lancet 1989; 335: 1403.
13. Bell BA, Kurczynski EM, Bergman G. Inhibitors to monoclonal antibody purified factor VIII (letter). Lancet 1990; 336: 638.
14. Ehrenforth S, Kreuz W, Scharrer I, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
15. Ljung R, Petrini P, Lindgren A, Tengborn L, Nilsson IM. Factor VIII and factor IX inhibitors in haemophiliacs (letter). Lancet 1992; 339: 1550.
16. de Biasi R, Rocino A, Papa ML, Salerno E, Mastrullo L, de Biasi D. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates. Thromb Haemost 1994; 71: 544-7.
17. Lusher J, Arkin S, Hurst D. Recombinant FVIII (Kogenate) treatment of previously untreated patients (PUPs) with hemophilia A. Update of safety, efficacy and inhibitor development after seven study years. Abstract no. PD-664, ISTH Florence. Thromb Haemost 1997; (Suppl.): 162.
18. Gruppo R, Chen H, Schroth P, Bray GL. Safety and immunogenicity of recombinant factor VIII (Recombinate) in previously untreated patients (PUPs). A 7.3 year update. Abstract no. 291, XXIII Congress of the WFH, The Hague. Haemophilia; 4: 228.
19. Schwaab R, Brackmann H-H, Meyer C, et al. Haemophilia A: Mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74: 1402-6.
20. Rothschild C, Laurian Y, Satre EP, et al. Inhibitor incidence in French previously untreated patients (PUPs) with severe hemophilia A receiving recombinant factor VIII. One-year additional exposure to rFVIII. Abstract no. 285, XXIII Congress of the WFH, The Hague. Haemophilia 1998; 4: 227.
21. Addiego JE, Kasper C, Abildgaard C, et al. Increased frequency of inhibitors in African American hemophilia A patients. Abstract no. 943, ASH Nashville. Blood 1994; 84 (Suppl. 1): 239.
22. Oldenburg J, Picard JK, Schwaab R, Brackmann H-H, Tuddenham EGD, Simpson E. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost 1997; 77 (2): 238-42.
23. McMillan CW, Shapiro SS, Whitehurst D, et al. The natural history of factor VIII:C inhibitors in patients with hemophilia A. A national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. Blood 1988; 71: 344-8.
24. Schwaab R, Oldenburg J, Schmitt C, Albert T, Brackmann H-H. Gene defect and inhibitor risk. Abstract no. 341, GTH Vienna. Ann Hematol 1997; 74 (Suppl. 2): A144.
25. Tizzano EF, Altisent C, Domènech M, Cornet M, Tusell J, Baiget M. Inhibitor development in haemophilia A patients with inversion of the intron 22 of the factor VIII gene. Thromb Haemost 1996; 76: 124-8.
26. Antonarakis SE, Kazazian HH, Tuddenham EGD. Molecular etiology of factor VIII deficiency in hemophilia A. Human Mutation 1995; 5: 1-22.
27. Frommel D, Muller JY, Prou-Wartelle O, Allain JP. Possible linkage between the major histocompatibility complex and the immune response to factor VIII in classical haemophilia. Vox Sang 1977; 33: 270-2.
28. Frommel D, Allain JP, Saint-Paul E, et al. HLA antigens and factor VIII antibody in classic hemophilia. Thromb Haemost 1981; 46: 687-9.
29. Lippert LE, Fisher JMcA, Schook LB. Relationship of major histocompatibility complex class II genes to inhibior formation in haemophilia A. Thromb Haemost 1990; 64: 564-8.
30. Hay CRM, Ollier W, Pepper L, et al. HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. Thromb Haemost 1997; 77: 234-7.
31. Ollier W, Hay CRM, Pepper L, et al. HLA class II profile: a determinant of inhibitor development in severe haemophilia A. Abstract no. PS-2657, ISTH Florence. Thromb Haemost 1997; (Suppl.): 651.
32. Rosendaal FR, Nieuwenhuis HK, van den Berg HM, et al. A sudden increase in factor VIII inhibitor development in multitransfused haemophilia A patients in the Netherlands. Blood 1993; 81: 2180-6.
33. Peerlinck K, Arnout J, Gilles JG, Saint-Remy J-M, Vermylen J. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb Haemost 1993; 69: 115-18.
34. Effenberger W, Oldenburg J, Budde U, et al. Entwicklung von Faktor-VIII-Hemmkörpern bei zuvor behandelten Patienten (PTP) mit schwerer Hämophilie A unter Anwendung eines doppelt virusinaktivierten plasmatischen Faktor-VIII-Konzentrats (Octavi SD Plus). 26. Hämophilie-Symposium Hamburg, 1995. Scharrer I, Schramm W (eds). Berlin/Heidelberg: Springer-Verlag, 1997.
35. Peerlinck K, Arnout J, Di Giambattista M, et al. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate. Thromb Haemost 1997; 77: 80-6.
36. Barrowcliffe TW, Di Giambattista M, Raut S, et al. Modification of FVIII in therapeutic concentrates after virus inactivation by solvent-detergent and pasteurisation. Abstract no. SC-2354, ISTH Florence. Thromb Haemostas 1997; (Suppl.): 576.
37. Laub R, di Giambattista M, Fondu P, Brackmann H-H, Lenk H, Scandella D. Restricted epitope specificity of factor VIII inhibitors which appeared in previously treated hemophiliacs after infusion with OCTAVI SD plus. Abstract no. OC-2409, ISTH Florence. Thromb Haemost 1997; (Suppl.): 590.
38. DiMichele DM, Aledort LM. Inhibitor development with post-licensure use of recombinant factor VIII (rFVIII): The US hemophilia region II experience. Abstract no. PS-350, ISTH Florence. Thromb Haemost 1997; (Suppl.): 87.
39. Gringeri A, Kreuz W, Escuriola-Ettinghausen C, et al. Anti-FVIII inhibitor incidence in previously untreated patients (PUPs) with hemophilia exposed to Kogenate (G.I.P.S.I. - German-Italian PUP Study on Inhibitor). Abstract no. 2642, ISTH Florence. Thromb Haemost 1997; (Suppl.): 648.
40. Lusher JM, Courter S, Spira J. Safety, efficacy and inhibitor development in previously untreated patients (PUPs) treated exclusively with recombinant B domain deleted FVIII (rFVIII SQ). Abstract no. 284, XXIII Congress of the WFH, The Hague. Haemophilia 1998; 4: 227.
41. Addiego J, Kasper C, Abildgaard C, et al. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. Lancet 1993; 342: 462-4.
42. Muntean W, Male Ch, Streif W, et al. Low inhibitor incidence in children treated with pasteurised human factor VIII. Abstract no. PS-2640, ISTH Florence. Thromb Haemost 1997; (Suppl.): 647.
43. Scharrer I, Neutzling O. Incidence of inhibitors in haemophiliacs. A review of the literature. Blood Coagulation Fibrinolysis 1993; 4: 753-8.
44. Pasi KJ, Hamon MD, Perry DJ, Hill FGH. Factor VIII and IX inhibitors after exposure to heat-treated concentrates. Lancet 1987; 329: 689.
45. Yee TT, Williams MD, Hill FGH, Lee CA, Pasi KJ. Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII product. Thromb Haemost 1997; 78: 1027-9.
46. Guérois C, Laurian Y, Rothschild C. Incidence of factor VIII inhibitor development in severe hemophilia A patients treated only with one brand of highly purified plasma-derived concentrate. Thromb Haemost 1995; 73: 215-18.
47. Peerlinck K, Rosendaal FR, Vermylen J. Incidence of inhibitor development in a group of young hemophilia A patients treated exclusively with lyophilized cryoprecipitate. Blood 1993; 81: 3332-5.
48. Tuddenham EGD, Lalloz MRA, Michaelides K, Esmon PC, Hurst D. Rapid screening of the factor VIII gene by multiplexed SSCP. Application to patients developing inhibitors during treatment with recombinant factor VIII. Abstract no. 1768 ASH St. Louis. Blood 1993; 82 (Suppl. 1): 446a.
49. Williams IJ, Peake IR, Goodeve AC, and the Recombinate™ PUP Study Group. Recombinate™ PUP mutation study: Relationship between factor VIII mutation and inhibitor development. Abstract no. 290, XXIII Congress of the WFH, The Hague. Haemophilia 1998; 4: 228.
50. Lee ML, Schroth P, Bray G, Gomperts ED. Determination of inhibitor-risk after receiving significant amounts of factor VIII concentrates. Abstract no. PS-2648, ISTH Florence. Thromb Haemost 1997; (Suppl.): 648.
51. White IIGC, Courter S, Bray GL, Lee M, Gomperts ED. A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. Thromb Haemost 1997; 77: 660-7.
52. Schwartz RS, Abildgaard CF, Aledort LM, et al. Human recombinant DNA-derived antihemophilic factor (Factor VIII) in the treatment of Hemophilia A. N Engl J Med 1990; 323: 1800-5.
53. Aygören-Pürsün E, Scharrer I, and the German Kogenate Study Group. A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A. Thromb Haemost 1997; 78: 1352-6.
54. Bray GL, Gomperts ED, Courter S, et al. A multicenter study of recombinant factor VIII (Recombinate): Safety, efficacy, and inhibitor risk in previously untreated patients. Blood 1994; 83: 2428-35.
55. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS, et al. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. N Engl J Med 1993; 328: 453-9.
56. Kreuz W, Auerswald G, Budde U, et al. Inhibitor incidence in previously untreated patients (PUPs) with hemophilia A and B. Abstract no. 286. XXIII Congress of the WFH, The Hague. Haemophilia 1998; 4: 227.
57. Kreuz W, Ehrenforth S, Funk M, et al. Immune tolerance therapy in pediatric haemophiliacs with factor VIII inhibitors: 14 years follow-up. Haemophilia 1995; 1: 24-32.
58. Pollmann H, Richter H. Transient factor VIII inhibitors in two patients with hemophilia A. Abstract no. PS-2658, ISTH Florence. Thromb Haemost 1997; (Suppl.): 651.
59. Ehrlich HJ, Bray GL, Gomperts ED. Comparison of high responder inhibitor frequency in recent studies of previously untreated patients with hemophilia A. Thromb Haemost 1998; 79: 242-3.
60. Scharrer I, Neutzling O, Schwaab R, Oldenburg J, Ehrlich H. Experiences with recombinant factor VIII products - development of inhibitors and immune tolerance therapy. Ann Hematol 1998; 76: A1-A6.
61. Sultan Y, and the French Hemophilia Study Group. Prevalence of inhibitors in a population of 3435 hemophilia patients in France. Thromb Haemost 1992; 67: 600-2.